Beacon Pointe Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE: EW) duri

On August 26, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company tha

Bank of Nova Scotia bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the

EP Wealth Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during t

B. Metzler seel. Sohn and Co. AG acquired a new position in Edwards Lifesciences Corporation (NYSE:

Allworth Financial LP bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during th

EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain

Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 7.93% on an ann

BlackRock Inc. bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the secon

Baxter Bros Inc. purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE: EW) duri

Bank Hapoalim BM purchased a new stake in Edwards Lifesciences Corporation (NYSE: EW) during the und

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium

Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 1.31% on an ann

Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation rai

On August 05, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company tha

Glenmede Trust Co. NA trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE: EW) by

Investors need to pay close attention to EW stock based on the movements in the options market latel

JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:EW) with a Overweight and ra

Piper Sandler analyst Adam Maeder reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and

Edwards Lifesciences Corp. (NYSE:EW) stock rose Friday after the medical device maker reported secon

Edwards Lifesciences tops Q2 Wall Street estimates with $1.74B in revenue. EW stock jumps as analyst

EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy a

U.S. stock futures were higher on Friday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose,

US stock futures mixed, focus on companies like American Express, Deckers, Verizon, Edwards Lifescie

Total Sales: $1.74 billion, a 12.5% increase year-over-year.Adjusted EPS: $0.78 for the quarter.TAVR

Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call Transcript

Edwards Lifesciences NYSE: EW reported stronger-than-expected second-quarter 2026 results, with mana

Edwards Lifesciences (NYSE:EW) is looking for Q3 Adj EPS of $0.71-$0.77 vs $0.74 analyst estimate. s

Edwards Lifesciences (NYSE:EW) affirms FY2026 Adj EPS guidance from $2.95-$3.05 to $2.95-$3.05 vs $3

Edwards Lifesciences (NYSE:EW) reported quarterly earnings of $0.78 per share which beat the analyst

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quar

Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Hold a

Mizuho analyst Anthony Petrone maintains Edwards Lifesciences (NYSE:EW) with a Outperform and rai

RBC Capital analyst Shagun Singh maintains Edwards Lifesciences (NYSE:EW) with a Outperform and r

Wall St analysts changed outlook on top names. KBW cut AON PT to $400, Barclay's cut T PT to $24

Citigroup analyst Joanne Wuensch maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises t

Evercore ISI Group analyst Vijay Kumar maintains Edwards Lifesciences (NYSE:EW) with a Outperform

Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Cana

BTIG analyst Marie Thibault maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the pr

CMS proposes easing TAVR coverage rules and expanding access, a move analysts say could strengthen E

RBC Capital analyst Shagun Singh reiterates Edwards Lifesciences (NYSE:EW) with a Outperform and

TD Cowen analyst Joshua Jennings maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises t

Barclays analyst Matt Miksic maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raise

Edwards Lifesciences shares rise after Q1 earnings beat, with strong valve therapy growth and update

Evercore ISI Group analyst Vijay Kumar maintains Edwards Lifesciences (NYSE:EW) with a Outperform

Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Hold a

Canaccord Genuity analyst William Plovanic maintains Edwards Lifesciences (NYSE:EW) with a Hold a